DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it will hold a conference call tomorrow, Friday, March 12, 2010 to discuss the positive outcomes of a recent meeting with the United States Food and Drug Administration (FDA) regarding the clinical trial results of a Phase 3 investigational new drug, Lymphoseek®, and the development pathway for a new drug application for Lymphoseek. The Phase 3 clinical study (NEO3-05) was conducted in subjects diagnosed with either breast cancer or melanoma.
